EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy

Vlad Andrei Cianga, Ion Antohe, Cosmin Minciună, Angela Dăscălescu

Frontiers in Pharmacology · 19.12.2025 · 16

DOI: 10.3389/fphar.2025.1738558 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.12.2025. Verfasst von Vlad Andrei Cianga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Regional Oncology Institute, Iasi, Romania. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor–modified natural killer (CAR-NK) cells are emerging as a promising alternative to CAR-T therapies, offering advantages such as reduced toxicity, allogeneic feasibility, and flexible manufacturing. Current reviews cover NK biology and CAR engineering progress, yet lack a unified perspective that connects these advances. This review provides a novel synthesis by mapping specific tumor immune evasion mechanisms, including antigen loss, lineage plasticity, impaired antigen processing, epitope masking, and trogocytosis to corresponding next-generation CAR-NK engineering solutions. This “evasion-to-solution” framework highlights how innovations such as dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing directly mitigate known mechanisms that lead to therapeutic failure. By linking tumor biology to engineering strategy, this review offers a translational roadmap for the rational design of more adaptable and resilient CAR-NK therapies.

Schlagwörter

Stichwörter der Autor:innen

CAR engineeringCAR-NK cell therapyCRSICANSadoptive cell immunotherapy (APC)cytokine release syndromeimmune effector cell-associated neurotoxicity syndromeimmunotherapy

Autor:innen und Institutionen

  • Hematology Department, Regional Oncology Institute, Iasi, Romania.
  • Grigore T Popa University of Medicine and Pharmacy Iasi, Iasi, Romania.
  • Bone Marrow Transplant Department, Regional Oncology Institute, Iasi, Romania.

Zitieren

APA

Cianga, V. A., Antohe, I., Minciună, C., & Dăscălescu, A. (2025). Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1738558

Vancouver

Cianga VA, Antohe I, Minciună C, Dăscălescu A. Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1738558

BibTeX
@article{Cianga2025,
  author = {Cianga, Vlad Andrei and Antohe, Ion and Minciună, Cosmin and Dăscălescu, Angela},
  title = {Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1738558}
}
Kostenlos starten →